2024
Vaccination to Prevent Lyme Disease: A Movement Towards Anti-Tick Approaches
Johnson E, Hart T, Fikrig E. Vaccination to Prevent Lyme Disease: A Movement Towards Anti-Tick Approaches. The Journal Of Infectious Diseases 2024, 230: s82-s86. PMID: 39140718, PMCID: PMC11322886, DOI: 10.1093/infdis/jiae202.Peer-Reviewed Original ResearchConceptsTransmission of tick-borne pathogensTick-borne pathogensIxodes spp ticksInhibited tick feedingTick feedingDisease vaccineTick vectorWildlife reservoirsOuter surface protein ALyme disease vaccineLyme diseaseTicksBorrelia burgdorferiLyme disease casesPreventing Lyme diseasePathogensFood and Drug AdministrationSurface protein AOspA-based vaccinesVaccineFeedingLymeProtein AFoodPrevent transmission
2015
Ixodes scapularis dystroglycan-like protein promotes Borrelia burgdorferi migration from the gut
Coumou J, Narasimhan S, Trentelman JJ, Wagemakers A, Koetsveld J, Ersoz JI, Oei A, Fikrig E, Hovius JW. Ixodes scapularis dystroglycan-like protein promotes Borrelia burgdorferi migration from the gut. Journal Of Molecular Medicine 2015, 94: 361-370. PMID: 26594018, PMCID: PMC4803822, DOI: 10.1007/s00109-015-1365-0.Peer-Reviewed Original ResearchConceptsB. burgdorferi transmissionTick gutLyme borreliosisTick feedingMurine modelVaccine targetsUninfected ticksRNA interferenceInfected ticksSalivary glandsBorrelia burgdorferiPotential targetGut tissueB. burgdorferiCausative agentIxodes ticksGutPrevious screeningTick proteinsGut cellsBurgdorferiMiceTicks resultsBorreliosisConfocal microscopy
2014
Vaccine development: how scientific collaboration and communication help prevent the spread of disease: an interview with Erol Fikrig, MD.
Fikrig E, Turchick A, Czochor J. Vaccine development: how scientific collaboration and communication help prevent the spread of disease: an interview with Erol Fikrig, MD. The Yale Journal Of Biology And Medicine 2014, 87: 519-25. PMID: 25506284, PMCID: PMC4257037.Peer-Reviewed Original Research
2003
An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine
Schoen RT, Deshefy-Longhi T, Van-Hoecke C, Buscarino C, Fikrig E. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine. Clinical Therapeutics 2003, 25: 210-224. PMID: 12637121, DOI: 10.1016/s0149-2918(03)90027-0.Peer-Reviewed Original ResearchConceptsLyme disease vaccineFirst booster doseSecond booster doseBooster doseAdverse eventsBooster dosesPrimary seriesMonth 24Disease vaccineClinical trialsEfficacy trialsImmune responseIncidence of AEsPattern of AEsLyme diseaseMost adverse eventsGeometric mean titersTotal IgG antibodiesProportion of subjectsPositive test resultsSeroprotective levelsBooster vaccinationMonth 36Third vaccinationDiary cards
2002
The Lyme Disease Vaccine Takes Its Toll
Thomas V, Fikrig E. The Lyme Disease Vaccine Takes Its Toll. Vector-Borne And Zoonotic Diseases 2002, 2: 217-222. PMID: 12804162, DOI: 10.1089/153036602321653798.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, BacterialAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferiHumansLipoproteinsLyme DiseaseLyme Disease VaccinesMembrane GlycoproteinsMiceMice, KnockoutReceptors, Cell SurfaceToll-Like Receptor 1Toll-Like Receptor 2Toll-Like ReceptorsConceptsTLR2-deficient miceToll-like receptorsPathogen-associated molecular patternsOspA antibodiesSpecific Toll-like receptorsBorrelia burgdorferi outer surface proteinDetectable humoral responseMolecular patternsProtective immune responseLyme disease vaccineDistinct pathogen-associated molecular patternsVaccine recipientsHumoral responseOspA vaccineCell surface expressionOspA vaccinationImmune responseDisease vaccineInnate responseTLR2Protective responseOuter surface proteinsTLR1Lyme diseaseDevelopment of responsesHyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice
Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT, Medzhitov R, Fikrig E, Flavell RA. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nature Medicine 2002, 8: 878-884. PMID: 12091878, DOI: 10.1038/nm732.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, BacterialAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferiCell SeparationCells, CulturedDrosophila ProteinsHumansInterleukinsLipoproteinsLyme Disease VaccinesMacrophagesMembrane GlycoproteinsMiceMice, KnockoutReceptors, Cell SurfaceSignal TransductionToll-Like Receptor 1Toll-Like Receptor 2Toll-Like ReceptorsConceptsToll-like receptor 1Less tumor necrosis factorTLR2-deficient miceLow antibody titersLyme disease vaccineTumor necrosis factorLow cell surface expressionOuter surface lipoproteinsVaccine recipientsAntibody titersInterleukin-6Cell surface expressionNecrosis factorOspA vaccinationDisease vaccineLow respondersInnate responseTLR2Low titersReceptor 1Substantial titersVaccinationMiceTLR1Borrelia burgdorferi
2001
Reactivity of dog sera to whole-cell or recombinant antigens of Borrelia burgdorferi by ELISA and immunoblot analysis
Magnarelli LA, Levy SA, Ijdo JW, Wu C, Padula SJ, Fikrig E. Reactivity of dog sera to whole-cell or recombinant antigens of Borrelia burgdorferi by ELISA and immunoblot analysis. Journal Of Medical Microbiology 2001, 50: 889-895. PMID: 11599738, DOI: 10.1099/0022-1317-50-10-889.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayWhole cell antigenRecombinant antigensB. burgdorferiNon-vaccinated dogsPolyvalent enzyme-linked immunosorbent assaysCanine borreliosisTick-infested areasTotal immunoglobulinWhole-cell B. burgdorferiAntibody titresBorrelia burgdorferi sensu strictoVaccinated dogsJoint disordersImmune responseBurgdorferi sensu strictoAntigenImmunosorbent assaySerumDogsNatural infectionInhibition of Borrelia burgdorferi-Tick Interactions In Vivo by Outer Surface Protein A Antibody
Pal U, Montgomery R, Lusitani D, Voet P, Weynants V, Malawista S, Lobet Y, Fikrig E. Inhibition of Borrelia burgdorferi-Tick Interactions In Vivo by Outer Surface Protein A Antibody. The Journal Of Immunology 2001, 166: 7398-7403. PMID: 11390491, DOI: 10.4049/jimmunol.166.12.7398.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Bacterial AgentsAntibodies, BacterialAntibodies, MonoclonalAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesBinding Sites, AntibodyBorrelia burgdorferi GroupDigestive SystemEpitopesFemaleImmune SeraInjections, IntraperitonealInjections, SubcutaneousIxodesLipoproteinsLyme DiseaseLyme Disease VaccinesMiceMice, SCIDMutationProtein Structure, TertiaryRecombinant ProteinsConceptsB. burgdorferi sensu strictoBurgdorferi sensu strictoB. burgdorferi N40Treatment of miceOuter Surface ProteinsB. burgdorferi sensu lato genospeciesSurface protein AOuter surface protein ASCID miceMurine modelB. burgdorferi attachmentLyme diseaseMiceB. burgdorferiBorrelia afzeliiB. afzeliiTick gutBorrelia gariniiOspAVivoAdherenceAntiserumPresent studySurface proteinsGut